HCP
AZN icon

Hexagon Capital Partners’s AstraZeneca AZN Stock Holding History

Hexagon Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,209
Closed -$238K – 270
2026
Q1 		$238K Buy
+1,209
New +$233K 0.03% 220
2025
Q2 		– Sell
-1,788
Closed -$263K – 228
2025
Q1 		$263K Buy
1,788
+10
+0.6% +$1.45K 0.05% 173
2024
Q4 		$233K Sell
1,778
-584
-25% -$81.8K 0.04% 193
2024
Q3 		$368K Buy
2,362
+16
+0.7% +$2.58K 0.07% 127
2024
Q2 		$366K Buy
2,346
+724
+45% +$109K 0.08% 129
2024
Q1 		$220K Buy
1,622
+146
+10% +$19.3K 0.05% 189
2023
Q4 		$199K Buy
1,476
+568
+63% +$73.8K 0.05% 198
2023
Q3 		$123K Sell
908
-144
-14% -$19.7K 0.03% 233
2023
Q2 		$151K Buy
1,052
+240
+30% +$35.3K 0.04% 200
2023
Q1 		$113K Buy
812
+71
+10% +$9.55K 0.03% 226
2022
Q4 		$100K Buy
741
+102
+16% +$12.8K 0.03% 243
2022
Q3 		$70K Buy
639
+272
+74% +$34.5K 0.02% 301
2022
Q2 		$48K Buy
367
+255
+228% +$33.5K 0.01% 369
2022
Q1 		$15K Hold
112
– – ﹤0.01% 561
2021
Q4 		$13K Sell
112
-37
-25% -$4.35K ﹤0.01% 568
2021
Q3 		$18K Hold
149
– – 0.01% 509
2021
Q2 		$18K Sell
149
-18
-11% -$1.98K 0.01% 478
2021
Q1 		$16K Buy
167
+130
+351% +$13.1K ﹤0.01% 462
2020
Q4 		$3K Sell
37
-27
-42% -$2.86K ﹤0.01% 591
2020
Q3 		$6K Buy
+64
New +$7.12K ﹤0.01% 509

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Hexagon Capital Partners's AZN Position: Q2 2026 in Review

Hexagon Capital Partners sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,209 shares — an estimated $238K sold.

Hexagon Capital Partners first reported a position in AZN in Q3 2020 and held it in 20 quarters. The position peaked at $368K in Q3 2024. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Hexagon Capital Partners reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Hexagon Capital Partners sold 1,209 AstraZeneca shares in Q2 2026, an estimated $238K.
  • Hexagon Capital Partners first reported a position in AstraZeneca in Q3 2020 and held it in 20 quarters.
  • Hexagon Capital Partners's AstraZeneca position peaked at $368K in Q3 2024.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Hexagon Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.